ClinicalTrials.gg
Drug

STA 9090 clinical trials

Also written STA-9090 and Ganetespib.

studies test it
38
open now
1
in phase 3
2
first study started
2007

How each study uses STA 9090 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the STA 9090 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Hsp90 inhibitor STA-9090
5
STA-9090 (ganetespib)
2

Development codes

STA-9090
22

Other names

Ganetespib
22

Studies by the year they started

38 studies that test it; most in 2010 (9)

Studies that test STA 9090, by start year
YearStudies
20072
20093
20109
20116
20126
20134
20145
20151
20161
20181

Who runs them

Industry 11 · Other 27

Synta Pharmaceuticals Corp. (11) · Memorial Sloan Kettering Cancer Center (4) · Dana-Farber Cancer Institute (3) · Emory University (3) · Massachusetts General Hospital (2) · Universitaire Ziekenhuizen KU Leuven (1) · University College, London (1) · M.D. Anderson Cancer Center (1)

Often tested with

Tested in the same studies.

Plerixafor (1) · Quizartinib (1) · Trastuzumab (1) · Ganitumab (1) · Ado-Trastuzumab Emtansine (1) · Pertuzumab (1) · Veliparib (1) · Neratinib (1)

Studies

Open first, then newest update. How each study uses STA 9090 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 38

See all 38 studies that test STA 9090 →